956 Retifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: results from the POD1UM-101 study

• Domenica Lorusso,
• Laurence Gladieff,
• Patricia Pautier,
• Christine Gennigens,
• Chuan Tian,
• Anna Kryzhanivska,
• Nawel Bourayou,
• Dominique Berton,
• Sulabha Ranganathan

Affiliations

Domenica Lorusso

1 Department of Women and Child Health, Division of Gynaecologic Oncology, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome, Lazio, Italy

Laurence Gladieff

Department of Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, Occitanie, France

Patricia Pautier

Department of Medical Oncology, Gustave Roussy Institute, Villejuif, Île-de-France, France

Christine Gennigens

3 Medical Oncology, Central University Hospital of Liege, Liege, Belgium

Chuan Tian

Incyte Corporation, Wilmington, DE, USA

Anna Kryzhanivska

4Regional Clinical Oncology Center, Ivano-Frankivsk, Ukraine

Nawel Bourayou

6Incyte Corporation, Wilmington, DE, USA

Dominique Berton

1GINECO and Institut de Cancérologie de l’Ouest (ICO), Centre René Gauducheau, Saint-Herblain, France

Sulabha Ranganathan

7Incyte Corporation, Wilmington, DE, USA